（3）2组有0.5%的患者出现钆（Gd）增强T1病变。NOVA研究是在对TOUCH处方项目进行分析之后启动的，旨在评估Tysabri Q6W IV给药方案的疗效。TOUCH处方项目分析显示，延长的给药间隔与PML概率的显著降低相关。来自TOUCH研究的最新数据分析表明，与批准的Q4W IV方案相比，平均Q6W给药方案与PML概率降低88%相关（危险比0...
5.2.TYSABRITOUCHPrescribingProgram TYSABRIisavailableonlythrougharestrictedprogramunderaREMScalledtheTOUCH® PrescribingProgrambecauseoftheriskofPML[seeWarningsandPrecautions(5.1)]. ReferenceID: ® Forprescribersandpatients,theTOUCHPrescribingProgramhastwocomponents:MS ®® TOUCH(forpatientswithmultiplesclerosis)...
TOUCHPrescribingProgram(TYSABRIOutreach; UnifiedCommitmenttoHealth) ♦ StatusupdateonMSriskmanagementplan ♦ Changestoriskmanagementplanwithaddition ofCDindication 3 TYSABRIRiskManagementGoals ♦ GoalsandactivitiesdevelopedincollaborationwithFDA ♦ Riskminimization ...
ResearchGate www.socolar.com touchneurology.com touchneurology.com (全网免费下载) 相似文献 引证文献Cost-Effectiveness Analyses of Natalizumab (Tysabri) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Mult... Background Natalizumab (Tysabri) is a new diseas...